Clinical trial · Interventional
Chemotherapy in Treating Patients With Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor
A Phase II Study to Evaluate the Role of Weekly Cisplatin With Oral Etoposide in Ewing's Sarcoma and Primitive Neuroectodermal Tumor (PNET) With Bone and/or Bone Marrow Metatstatic Disease
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): low accrual
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have metastatic Ewing's sarcoma or primitive neuroectodermal tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 65 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed Ewing's family tumor as characterized by the following:
* Positive MIC2 on immunohistochemistry OR
* Evidence of a chromosomal translocation involving the EWS gene by conventional cytogenetics
* t(11; 22) translocation or variant OR
* Demonstration of EWS/FLI1 or EWS/ERG gene fusion by PCR or FISH
* Metastases outside the lung or pleura
* At least 1 measurable lesion outside of previously irradiated area
* No symptomatic or known CNS metastases
PATIENT CHARACTERISTICS:
Age:
* 15 to 65
Performance status:
* WHO 0-2
Life expectancy:
* Not specified
Hematopoietic:
* WBC at least 3,000/mm3
* Neutrophil count at least 2,000/mm3
* Platelet count at least 100,000/mm3
Hepatic:
* Bilirubin less than 3 mg/dL
* Albumin greater than 2.5 g/dL
Renal:
* Creatinine less than 1.2 mg/dL
* Creatinine clearance greater than 70 mL/min
Cardiovascular:
* No history of uncontrolled cardiovascular disease
Other:
* No other severe medical illness, including psychosis
* No other prior primary malignancy except adequately treated carcinoma in situ of the cervix or basal cell skin cancer
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* See Disease Characteristics
Surgery:
* Not specifiedReferences
Publications (0)
Data not yet available